Nexalin Technology

NXL

시가총액 US$246만

Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs

Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers

Appointment as Senior Strategic Advisor marks the Company's expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America DiTota spent over two decades in neuromodulation at Abbott and Medtronic, two of the largest companies in the field, including responsibility for Abbott's North America commercial neuromodulation business, a division representing approxim ately $700 million in business Nexalin's Gen-2 SYNC device is already approved in China, Brazil, Oman and Israel; the engagement is intended to build the distribution relationships, go-to-market plan and commercial infrastructure required to convert those approvals into commercial sales HOUSTON, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology, today announced the appointment of Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15, 2026.

Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer's patients

HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil

Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life

Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation

U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury